Clinical Trial Detail

NCT ID NCT02960022
Title A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
Recruitment Recruiting
Gender male
Phase Phase II
Variant Requirements No
Sponsors Astellas Pharma Global Development, Inc.
Indications

prostate cancer

Therapies

Abiraterone + Enzalutamide + Prednisone

Enzalutamide

Age Groups: adult senior

No variant requirements are available.